Building a Successful Future of Work in This Disrupted World

Since the COVID-19 pandemic, there has been a huge shift in how we approach our work lives, so how do we take advantage of this shift to build a successful future of work that fits both employers and employees? Different opinions are flying around about what works best regarding issues such as burnout, how to increase productivity while minimizing distractions working from home, how to feel more connected, and finding meaning by not allowing work to define our sense of purpose.

On this episode of DisruptED, host Ron J Stefanski speaks with Karen Mangia, a tech warrior and the current VP of Market Insight for Salesforce, about success from anywhere as it relates to the shift in our relationship with work and how work fits into our lives.

“The challenge of success from anywhere is that it draws a line in the sand that paints this polar opposite of winners and losers, employer versus employee, work well and live well; these things do not have to be mutually exclusive and the organizations winning at this new world of work are all asking the same question of ‘what matters? And from this question, we have the opportunity to create choices,” said Mangia.

Ron and Karen discussed the future of work…

● Navigating the world of work: what does the future of work look like?

● Resetting the expectations of our employer

● How to have more GSD women in higher positions in tech

“Our expectation is moving from control to a community—a place of shared identity—like a kaleidoscope identity where brilliant individual pieces change their patterns with a little bit of influence,” said Mangia. “Great communities are based primarily on shared values,” she said further.

Karen Mangia received her Bachelor’s degree in International Business as well as her Master’s in Information and Communication Sciences from Ball State University.  In her career, Mangia is not only a force at Salesforce, but she is also a Wall Street Journal best-selling author, keynote speaker, executive coach and that is only a short list of the many roles she holds in her industry.

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More